Medicine
Nurtec ODT 75 mg orally disintegrating tablet
Nurtec ODT 75 mg orally disintegrating tablet is a prescription medicine containing Rimegepant for oral use, marketed by Pfizer Laboratories, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store NURTEC ODT at controlled room temperature, 20°C to 25°C (68°F to 77°F)…
Key facts
- Active ingredient (INN)
- Rimegepant
- Brand
- Nurtec ODT
- Strength
- 75 mg
- Dosage form
- Orally disintegrating tablet
- Route
- Oral
- Packs
- 1 blister pack
- Marketing authorisation holder
- Pfizer Laboratories
- Manufacturers
- Pfizer LaboratoriesSportpharm
- Origin register
- US FDA, United States
- Storage
- Store NURTEC ODT at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N02CD06 Rimegepant
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 5 March 2020
- Identifiers
- RxCUI 2282313, 2282320DailyMed set ID 9ef08e09-1098-35cc-e053-2a95a90a3e1d, 86ef19d2-d6dc-4ac1-a793-dc549cc6bb9bNDC 72618-3000, 85766-096, 72618-3001Application NDA212728
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 blister pack in 1 carton / 8 tablet, orally disintegrating in 1 blister pack | 72618-3000-2 | Pfizer Laboratories | 5 March 2020 |
| 1 blister pack in 1 carton / 8 tablet, orally disintegrating in 1 blister pack | 85766-096-08 | Sportpharm | 14 October 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Rimegepant is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults, among other approved uses. It is available as orally disintegrating tablets. MedsAcross supplies Rimegepant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RimegepantFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- NURTEC ODT prescribing information (Pfizer Laboratories) · U.S. National Library of Medicine, DailyMed
- Vydura: European public assessment report (EPAR) · European Medicines Agency
Need Nurtec ODT 75 mg orally disintegrating tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.